6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine
C25H24FN7 — CID 126607717
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine
6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine (PubChem CID 126607717) has the molecular formula C25H24FN7 and a molecular weight of 441.51 g/mol. Its IUPAC name is 6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine.
Molecular Properties
| Compound Name | 6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine |
|---|---|
| PubChem CID | 126607717 |
| Molecular Formula | C25H24FN7 |
| Molecular Weight | 441.51 g/mol |
| Exact Mass | 441.21 |
| IUPAC Name | 6-[3-(4-fluorophenyl)-1-methylpyrazol-4-yl]-2-[(E)-2-(5-pyrrolidin-1-yl-2-pyridinyl)ethenyl]pyridazin-3-imine |
| SMILES | [H]/N=c1\ccc(-c2cn(C)nc2-c2ccc(F)cc2)nn1/C=C/c1ccc(N2CCCC2)cn1 |
| InChI | InChI=1S/C25H24FN7/c1-31-17-22(25(30-31)18-4-6-19(26)7-5-18)23-10-11-24(27)33(29-23)15-12-20-8-9-21(16-28-20)32-13-2-3-14-32/h4-12,15-17,27H,2-3,13-14H2,1H3/b15-12+,27-24+ |
| InChIKey | SWROHKNOCXIKAL-LYDMCEBASA-N |
| XLogP | 4.19 |
| TPSA | 75.62 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 441.51 |
| LogP ≤ 5 | 4.19 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126607717 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.